receptor agonist raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-04-25 and is reviewed periodically as new material appears.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, developed by Novo Nordisk and first approved in 2017 for type 2 diabetes. It belongs to the incretin mimetic class, a group of agents that reproduce the glucose-dependent actions of endogenous GLP-1. The molecule was engineered to resist degradation by dipeptidyl peptidase-4 and to bind serum albumin, extending its half-life from minutes to roughly one week. Approval for chronic weight management followed in 2021, based on large cardiovascular and obesity outcome trials.
GLP-1 receptors are expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises cyclic AMP, enhances glucose-dependent insulin secretion, and suppresses glucagon release when blood glucose is high. Effects on gastric emptying and on hypothalamic appetite circuits reduce energy intake. Because insulin release remains glucose-dependent, the risk of hypoglycemia is low when the drug is used alone. The precise contribution of each pathway to body weight change in humans remains an area of active investigation.
Clinical studies of semaglutide generally measure glycated hemoglobin, fasting plasma glucose, body weight, and composite cardiovascular endpoints. The SUSTAIN program enrolled adults with type 2 diabetes, while the STEP program focused on obesity without diabetes. Administration follows a stepwise escalation schedule designed to limit gastrointestinal effects during the first weeks. Reported outcomes include mean percentage weight change, the proportion of participants reaching defined weight-loss thresholds, and rates of nausea, vomiting, and diarrhea. Long-term data on durability after treatment stops are still limited and remain a topic of ongoing research.
| Property | Value | Notes |
|---|---|---|
| Molecular class | 31-amino-acid peptide | Modified glucagon-like peptide-1 analogue |
| Molecular mass | approximately 4114 Da | Calculated for the free peptide backbone |
| Appearance | white to off-white powder | Typical of purified lyophilised peptide batches |
| Solubility class | freely soluble in water | Aqueous solubility improves at slightly alkaline pH |
| Typical storage | -20 degrees Celsius, dry, dark | Protect from repeated freeze-thaw cycles |
==== Combine technology ==== The Combine use an arsenal of science fiction technologies. They have access to teleportation technology, which transports them between dimensions. However, their teleporter technology is restrictive in comparison to that developed by Eli Vance, Isaac Kleiner and Judith Mossman in that it cannot be used to teleport to other locations within the same dimension. Throughout the games, various futuristic computer consoles, doors, power sources and weapon emplacements are encountered. In addition, the Combine employ the use of robotic drones called city scanners, to observe the citizens of Earth. They monitor individuals and take photographs, while combat drones called shield scanners are used to drop mines. Civil Protection makes use of smaller drones called manhacks, which are equipped with razor-sharp rotating blades to attack targets with laceration injuries. These are often deployed in closed-in areas. The Combine also use two types of land mines; hopper mines throw themselves into the air and detonate when an enemy is detected nearby, while spherical rollermines roll towards vehicles or enemies, attach themselves and deliver electrical attacks. Combine technology is also used to transform humans into Overwatch soldiers or Stalkers, deformed and mutilated humans with no memory of their past selves who act as slaves and maintenance workers in Combine facilities. Transformation into a Stalker is considered among the Combine's worst punishments for dissidents.
=== Calcium-sensing receptor (CaR) === The secretion of parathyroid hormone (PTH) is regulated by the interaction of the calcium-sensing receptor with calcium in the blood. The calcium-sensing receptor is present on the plasma membrane of the chief cells. The CaR is a G protein-coupled receptor, as part of the C family. The CaR is divided into three general domains. These include an NH2-terminal extracellular end, a COOH-terminal intracellular end, and seven transmembrane domains. The CaR interacts positively with phospholipase C (PLC) and adenylyl cyclase. The CaR includes phosphorylation sites for protein kinase C (PKC) and protein kinase A (PKA). The phosphorylation of the PLC is seen to inhibit the secretion of PTH due to high calcium levels in the blood. The function of the PKA sites is currently unknown.
For convenience, three different views of the data are available on Wikipedia: two sets of "segmented tables", and a single "unitized table (all elements)". The unitized table allows easy visualization of proton/neutron-count trends but requires simultaneous horizontal and vertical scrolling. The segmented tables permit easier examination of a particular chemical element with much less scrolling. Links are provided to quickly jump between the different sections.
Sources: en.wikipedia.org
In 1912, the first deposit of distinct, single-crystal turquoise was discovered at Lynch Station in Campbell County, Virginia. The crystals, forming a druse over the mother rock, are very small; 1 mm (0.04 in) is considered large. Until the 1980s Virginia was widely thought to be the only source of distinct crystals; there are now at least 27 other localities. In an attempt to recoup profits and meet demand, some American turquoise is treated or enhanced to a certain degree. These treatments include innocuous waxing and more controversial procedures, such as dyeing and impregnation (see Treatments). There are some American mines which produce materials of high enough quality that no treatment or alterations are required. Any such treatments which have been performed should be disclosed to the buyer on sale of the material.
MRI for imaging anatomical structures or blood flow do not require contrast agents since the varying properties of the tissues or blood provide natural contrasts. However, for more specific types of imaging, exogenous contrast agents may be given intravenously, orally, or intra-articularly. Most contrast agents are either paramagnetic (e.g.: gadolinium, manganese, europium), and are used to shorten T1 in the tissue they accumulate in, or super-paramagnetic (SPIONs), and are used to shorten T2 and T2* in healthy tissue reducing its signal intensity (negative contrast agents). The most commonly used intravenous contrast agents are based on chelates of gadolinium, which is highly paramagnetic. In general, these agents have proved safer than the iodinated contrast agents used in X-ray radiography or CT. Anaphylactoid reactions are rare, occurring in approx. 0.03–0.1%. Of particular interest is the lower incidence of nephrotoxicity, compared with iodinated agents, when given at usual doses—this has made contrast-enhanced MRI scanning an option for patients with renal impairment, who would otherwise not be able to undergo contrast-enhanced CT. Gadolinium-based contrast reagents are typically octadentate complexes of gadolinium(III). The complex is very stable (log K > 20) so that, in use, the concentration of the un-complexed Gd3+ ions should be below the toxicity limit.
=== Transportation === Rhodesia had its own road and rail network along with an airline, Air Rhodesia. The road network largely was found in white areas and there were by 1975 "about" 45,000 miles (72,000 km) of paved roads. The railroad network was 1,568 miles (2,523 km) long and matched the South African railroad gauge. Rhodesia also had connections via road and rail to neighboring countries.
Venom is found in some 200 cartilaginous fishes, including stingrays, sharks, and chimaeras; the catfishes (about 1,000 venomous species); and 11 clades of spiny-rayed fishes (Acanthomorpha), containing the scorpionfishes (over 300 species), stonefishes (over 80 species), gurnard perches, blennies, rabbitfishes, surgeonfishes, some velvetfishes, some toadfishes, coral crouchers, red velvetfishes, scats, rockfishes, deepwater scorpionfishes, waspfishes, weevers, and stargazers.
Sources: en.wikipedia.org
It is a glucagon-like peptide-1 receptor agonist, often grouped with the incretin mimetics. Its backbone is modified from the human hormone to resist enzymatic degradation and to bind albumin. These two features distinguish it from the native peptide.
No. It shares high sequence identity but carries non-natural modifications that alter its stability and clearance. The naturally occurring hormone is broken down within minutes, while the synthetic analogue circulates far longer.
Attachment to serum albumin reduces renal filtration of the peptide and shields it from enzymatic breakdown. The consequence is a much longer interval between administrations than unmodified peptides allow. The precise contribution of binding affinity to overall duration is still being quantified.
It is given either as a once-weekly subcutaneous injection or as an oral tablet taken once daily. The two forms use different absorption strategies, so they are not interchangeable on a milligram-for-milligram basis.